Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Company Overview - Inovio Pharmaceuticals is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating diseases, including those associated with human papillomavirus (HPV) [5]. Legal Allegations - The lawsuit claims that during the Class Period, Inovio made false and misleading statements, including: 1. Deficiencies in the manufacturing of Inovio's CELLECTRA device [5]. 2. Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. 3. Insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [5]. 4. Overstated regulatory and commercial prospects for INO-3107 [5]. - The lawsuit asserts that these misstatements led to investor damages when the true information became public [5]. Class Action Participation - Investors who purchased Inovio securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly [3][6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. - The lawsuit alleges that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Firm Background - Rosen Law Firm specializes in securities class actions and has a strong track record, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - The founding partner of Rosen Law Firm was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. related to alleged violations of federal securities laws, particularly concerning misleading statements about the company's manufacturing and regulatory processes for its INO-3107 treatment [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Inovio to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Inovio, with a deadline of April 7, 2026, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [5]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [6]. - Inovio announced it does not plan to pursue approval under the standard review timeline and will seek a meeting with the FDA to discuss options for accelerated approval [6]. - Following the FDA's announcement, Inovio's stock price dropped by $0.56, or 24.45%, closing at $1.73 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals for alleged violations of securities laws due to misleading statements regarding its manufacturing capabilities and regulatory submissions [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Inovio Pharmaceuticals for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Inovio's securities between October 10, 2023, and December 26, 2025, are encouraged to participate in the lawsuit before the deadline of April 7, 2026 [2]. - The lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device and the likelihood of filing the INO-3107 Biologics License Application (BLA) by the second half of 2024 [4]. Group 2: Allegations Against Inovio - The complaint alleges that Inovio suffered from manufacturing deficiencies and failed to provide sufficient evidence for an FDA priority review or accelerated approval for its BLA [4]. - As a result of these misleading statements, investors experienced damages when the truth about Inovio's situation was revealed [4].

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submi ...

New York, New York--(Newsfile Corp. - February 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026.SO WHAT: If you purchased Inovio securities during the Class ...

New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026.SO WHAT: If you purchased Inovio securities during the Class ...

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Inovio Pharmaceuticals, Inc., (“Inovio” or the "Company") (NASDAQ: INO) investors of a class action on behalf of investors that bought securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”). Inovio investors have until April 7, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options If you purchased or acquired Inovio securities between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- What’s Happening: B ...

INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Inovio] between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, c ...